Sunvozertinib (DZD9008) is an emerging next-generation, highly selective EGFR tyrosine kinase inhibitor (TKI) designed to target EGFR exon 20 insertion (Ex20ins) mutations, a subtype of non-small cell lung cancer (NSCLC) associated with poor response to earlier-generation EGFR TKIs. Patients with these mutations typically exhibit intrinsic resistance to approved standard EGFR inhibitors due to the altered conformation of the kinase domain. Consequently, therapeutic options have remained limited, and platinum-doublet chemotherapy has historically been the primary systemic treatment. Recently developed agents such as amivantamab and mobocertinib have improved response rates, yet challenges related to tolerability, CNS penetration, and durability of benefit persist. Sunvozertinib aims to address these limitations through rational structural design, optimized kinase selectivity, and improved safety-efficacy balance. Preclinical studies have shown potent inhibition of a broad spectrum of EGFR Ex20ins variants while sparing wild-type EGFR, suggesting a reduced risk of dose-limiting toxicities commonly seen with non-selective EGFR blockade. Sunvozertinib has also demonstrated promising CNS activity in animal models-an important feature for NSCLC patients, who frequently develop brain metastases. Early-phase clinical trials, including the WU-KONG series, have reported promising clinical efficacy, including objective response rates ranging from 44-60% in previously treated patients and meaningful activity in treatment-naïve cohorts. The tolerability profile of the drug seems manageable, with diarrhea, rash, and stomatitis among the most commonly observed adverse events; these, however, tend to be milder compared with other agents targeting EGFR Ex20ins.
Due to physiological constraints that negatively affect the efficiency of conventional ocular preparations, such as fast tear turnover, poor corneal penetration, as well as short in-precornereal resident times, ocular drug delivery has long been a technical challenge. Nanoemulsion strategies based on engineering principles have been identified as a promising solution to overcome these challenges for improved solubilization, ocular bioavailability, as well as drug preparation stability. An eye preparation nanoemulsion consists of water, an oil phase, surfactants, as well as a cosurfactant, forming a kinetically stable colloidal system characterized by a mean particle diameter measuring less than 200 nm. The design principles and translation properties of ocular nanoemulsion systems are discussed in this review. Formulation components and the manufacturing methods, along with the stability problems and recent advances, are discussed. The suitability of the systems to both high-energy production methods (such as spontaneous emulsification, ultrasonication, and high-pressure homogenization) and the stability of the ocular nanoemulsions and recent advances on novel methods such as stimuli-sensitive, mucoadhesive, or positive nanoemulsions will be discussed. Despite these advantages, however, some challenges such as stability for a extended period, complexity, and cost of production still exist. In conclusion, customized ocular nanoemulsion delivery systems are quite viable and flexible research strategies for successful ocular drug delivery.
AIM:The aim of this study is to highlight the emerging and advanced applications of quantum dots (QDs) beyond their conventional use, emphasizing their role in modern electronics, healthcare, energy systems, food safety, and smart materials Methods: This work is based on an extensive literature survey of recent research articles, reviews, and technological reports focusing on the optical, electronic, nonlinear, and thermoelectric properties of quantum dots. The collected data were systematically analyzed to understand how size-dependent properties of QDs enable their integration into diverse applications such as photodetectors, display technologies, biosensors, solar devices, and wearable healthcare systems. RESULT AND DISCUSSION:Quantum dots exhibit exceptional size-dependent optical and electronic properties that significantly enhance device performance across multiple sectors. In photodetectors, QDs improve sensitivity over a wide spectral range, while in QLED displays they provide high colour purity and energy efficiency. In the food industry, QD-based sensors enable rapid and accurate detection of pathogens, pesticides, and spoilage markers, improving food safety. Their incorporation into solar windows and photovoltaic glass allows sustainable energy generation without loss of transparency. In wearable healthcare devices, QDs facilitate real-time and non-invasive monitoring of vital biomarkers. Additionally, their nonlinear optical properties support advances in laser technology and optical communication, and their thermoelectric behavior contributes to efficient waste heat recovery and thermal management. These findings demonstrate the versatility and multifunctionality of quantum dots. CONCLUSION:Quantum dots represent a powerful class of nanomaterials with broad and transformative potential. Their unique physicochemical properties enable innovative applications across electronics, healthcare, energy, and smart materials. Continued research and technological development are expected to further expand their practical implementation, making quantum dots key components in next-generation sustainable and high-performance devices.
Benzimidazole remains a privileged heteroaromatic scaffold with broad therapeutic potential, spanning antimicrobial, anticancer, antitubercular, and antiviral domains. In recent years (2020-2025), computational methodologies have significantly accelerated benzimidazole-based drug discovery by elucidating structural determinants of activity and streamlining lead optimization. Molecular docking and dynamics simulations consistently reveal the scaffold's ability to engage in π-π stacking, hydrogen bonding, and hydrophobic interactions within protein active sites. Substituent modifications at C2, C5, and C6 critically modulate affinity and selectivity across diverse targets, including InhA, DprE1, kinases, and viral proteases. Complementary strategies such as QSAR, pharmacophore modeling, and in silico ADMET predictions strengthen early hit prioritization and reduce experimental attrition. Emerging approaches integrating artificial intelligence, machine learning, and free energy perturbation further enhance predictive accuracy and enable multi-target drug design. This short communication highlights recent computational insights, best practices, and future trends in benzimidazole research, emphasizing the value of combining docking, MD, QSAR, ADMET, and AI/ML workflows. Together, these advances provide a robust, cost-effective pipeline for the rational design of next-generation benzimidazole derivatives with improved efficacy and translational potential.
Bio electromedicine, a dynamic field at the intersection of biology and electromagnetism, has gained prominence in modern healthcare for its diverse applications. This comprehensive review examines the historical development, fundamentals, clinical applications, and challenges of bio electromedicine. The historical journey begins with early pioneers such as Luigi Galvani and Alessandro Volta, progresses through milestones like the invention of the ECG, and unfolds to the cutting-edge applications of today. The fundamentals section explores the collaboration of biological systems with electromagnetic fields, the principles of electrical stimulation, and their cellular and molecular mechanism. Bioelectromagnetic safety guidelines, exposure limits, and environmental concerns are also discussed, ensuring responsible integration into medical practice. Clinical applications encompass a wide array, from pain management and neurological disorders to cardiology, neuropsychiatry, oncology, and regenerative medicine. The field continues to evolve, with emerging research areas and technological advancements shaping the future. Personalized bioelectromedicine stands as an exciting frontier. Despite its promise, bioelectromedicine grapples with ethical considerations, the need for robust clinical evidence, public scepticism, and the integration with conventional medical practices. This review encourages further research and development in bioelectromedicine, fostering its potential to revolutionize healthcare and improve patient outcomes in the years to come.
